CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


PhysiotherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2145 SARS-Cov-2 infection Wiki 0.71

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D016638 Critical Illness NIH 0.10
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care Requiring Invasive Ventilation: An Observational Study

This is an observational study exploring the levels of mobility and rehabilitation in patients admitted to critical care with a confirmed diagnosis of COVID-19

NCT04396197 COVID-19 Critical Illness Ards ICU Acquired Weakness Other: Physiotherapy
MeSH:Critical Illness

Primary Outcomes

Description: Highest level of mobility achieved at the point of ICU discharge

Measure: Mobility level

Time: At ICU discharge, an average of 3 weeks

Description: Time taken to first mobilise, defined as sitting on the edge of the bed or higher

Measure: Time taken to first mobilise

Time: during ICU admission, up to 3 weeks

Secondary Outcomes

Description: Discharged to home, home with rehab, or a community rehab facility

Measure: Discharge location

Time: Hospital discharge, up to 2 months

2 The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients

Problems such as breathlessness, exercise intolerance and loss of peripheral muscle strength can be observed in individuals who have been diagnosed with COVID19 and have been discharged. In our study, it was aimed to investigate the effect of telerehabilitation physical therapy intervention to these cases by using videoconferencing method on the physical condition of the cases.

NCT04402983 Covid19 Telerehabilitation Physical Therapy Other: Physiotherapy

Primary Outcomes

Description: The mMRC Dyspnea Scale is best used to establish baseline functional impairment due to dyspnea attributable to respiratory disease; tracking the mMRC over time or with therapeutic interventions is of less certain clinical utility.The severity of dyspnea is rated on a scale of 0 to 4. "O" means no dyspnea perception, "4" means severe dyspnea perception.

Measure: Modified Medical Research Council Dyspnea Score

Time: Baseline to 6 weeks

Description: The Timed "Up and Go" (TUG) Test measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm, arm height 65 cm), walk a distance of 3 meters (approximately 10 feet), turn, walk back to the chair, and sit down. Normal healthy elderly usually complete the task in 10 seconds or less. Very frail or weak elderly with poor mobility may take 2 minutes or more. Clinical guide: <10 seconds = normal <20 seconds = good mobility, can go out alone, mobile without a gait aid <30 seconds = problems, cannot go outside alone, requires a gait aid A score of more than or equal to 14 seconds has been shown to indicate high risk of falls.

Measure: Timed up and go test

Time: Baseline to 6 weeks

Description: Visual analog scale to assess the pain on a horizontal, non-calibrated line of 100 mm, ranging from very low (0) to very high (100)

Measure: Visual analog scale to assess the pain severity

Time: Baseline to 6 weeks

Description: The Short Physical Performance Battery (SPPB) is comprised of 3 tasks: a standing balance test (side by side, semi-tandem and tandem), a 4-m habitual gait speed, and 5 sit to stand from a chair. Each task is scored (based on time) from 0-4 points. The total score is 12 points and this represents the highest performance. It can be easily performed at home via video conferencing

Measure: The Short Physical Performance Battery (SPPB)

Time: Baseline to 6 weeks

Description: Visual analog scale to assess the fatigue severity on a horizontal, non-calibrated line of 100 mm, ranging from very low (0) to very high (100)

Measure: Visual analog scale to assess the fatigue severity

Time: Baseline to 6 weeks

Secondary Outcomes

Description: This is a 21-item self-assessment scale designed by Aaron Beck in 1961 to measure the risk and level of depression.

Measure: BECK depression inventory

Time: Baseline to 6 weeks

Description: The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)

Measure: Saint George Respiratory Questionnaire

Time: Baseline to 6 weeks


No related HPO nodes (Using clinical trials)